Mahavir Narwade, Saili Jagdale, Kavita R. Gajbhiye
{"title":"N-acetyl-d-glucosamine decorated solid lipid nanoparticles for targeted tamoxifen delivery to breast cancer cells","authors":"Mahavir Narwade, Saili Jagdale, Kavita R. Gajbhiye","doi":"10.1007/s11051-024-06166-1","DOIUrl":null,"url":null,"abstract":"<div><p>One of the primary challenges associated with current chemotherapy lies in its inherent toxicity to healthy cells, leading to severe side effects. Recognizing the need for a more targeted approach, we have focused on tumor-specific drug delivery. Cancer cells, being highly metabolic, exhibit a significant increase in glucose consumption approximately 200 times more than normal cells for their rapid growth. To address this, we have engineered GLcNAc-modified solid lipid nanoparticles (SLNPs) designed to be actively internalized by cancer cells, thereby facilitating precise drug delivery to tumors. The developed GLcNAc-TMX-SLNPs are characterized by a size range of 200 to 250 nm and a surface charge of -25 to -35 mV. Their structural properties were thoroughly examined using techniques such as DSC, FTIR, and TEM. In the evaluation of drug release within the tumor microenvironment pH, a biphasic release pattern was observed, with 73.54 ± 0.73% release of TMX within 48 h. Importantly, the hemolysis caused by these developed SLNPs was found to be less than 5%, indicating their suitability for intravenous administration. Cellular uptake studies conducted on MDA-MB-231 cells underscored the targeted characteristics of the developed formulations. With a stable lipid composition, these SLNPs present a promising and stable platform for anticancer treatment. By minimizing off-target effects and enhancing drug delivery precision, our approach holds potential to improve the therapeutic efficacy of chemotherapy while mitigating its impact on healthy cells.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":653,"journal":{"name":"Journal of Nanoparticle Research","volume":"26 11","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanoparticle Research","FirstCategoryId":"88","ListUrlMain":"https://link.springer.com/article/10.1007/s11051-024-06166-1","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
One of the primary challenges associated with current chemotherapy lies in its inherent toxicity to healthy cells, leading to severe side effects. Recognizing the need for a more targeted approach, we have focused on tumor-specific drug delivery. Cancer cells, being highly metabolic, exhibit a significant increase in glucose consumption approximately 200 times more than normal cells for their rapid growth. To address this, we have engineered GLcNAc-modified solid lipid nanoparticles (SLNPs) designed to be actively internalized by cancer cells, thereby facilitating precise drug delivery to tumors. The developed GLcNAc-TMX-SLNPs are characterized by a size range of 200 to 250 nm and a surface charge of -25 to -35 mV. Their structural properties were thoroughly examined using techniques such as DSC, FTIR, and TEM. In the evaluation of drug release within the tumor microenvironment pH, a biphasic release pattern was observed, with 73.54 ± 0.73% release of TMX within 48 h. Importantly, the hemolysis caused by these developed SLNPs was found to be less than 5%, indicating their suitability for intravenous administration. Cellular uptake studies conducted on MDA-MB-231 cells underscored the targeted characteristics of the developed formulations. With a stable lipid composition, these SLNPs present a promising and stable platform for anticancer treatment. By minimizing off-target effects and enhancing drug delivery precision, our approach holds potential to improve the therapeutic efficacy of chemotherapy while mitigating its impact on healthy cells.
期刊介绍：
The objective of the Journal of Nanoparticle Research is to disseminate knowledge of the physical, chemical and biological phenomena and processes in structures that have at least one lengthscale ranging from molecular to approximately 100 nm (or submicron in some situations), and exhibit improved and novel properties that are a direct result of their small size.
Nanoparticle research is a key component of nanoscience, nanoengineering and nanotechnology.
The focus of the Journal is on the specific concepts, properties, phenomena, and processes related to particles, tubes, layers, macromolecules, clusters and other finite structures of the nanoscale size range. Synthesis, assembly, transport, reactivity, and stability of such structures are considered. Development of in-situ and ex-situ instrumentation for characterization of nanoparticles and their interfaces should be based on new principles for probing properties and phenomena not well understood at the nanometer scale. Modeling and simulation may include atom-based quantum mechanics; molecular dynamics; single-particle, multi-body and continuum based models; fractals; other methods suitable for modeling particle synthesis, assembling and interaction processes. Realization and application of systems, structures and devices with novel functions obtained via precursor nanoparticles is emphasized. Approaches may include gas-, liquid-, solid-, and vacuum-based processes, size reduction, chemical- and bio-self assembly. Contributions include utilization of nanoparticle systems for enhancing a phenomenon or process and particle assembling into hierarchical structures, as well as formulation and the administration of drugs. Synergistic approaches originating from different disciplines and technologies, and interaction between the research providers and users in this field, are encouraged.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
